MedTrace Logo

A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

NCT05476926 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 6000

Last updated 2026-03-16

No results posted yet for this study

Summary

The VOYAGER study is a primary data collection, non-interventional, prospective, multinational, multicenter study. It is designed to collect real-world, long-term data to explore long-term effectiveness, safety, clinical insights, treatment patterns, and factors driving the treatment decisions among patients being treated with specified Roche ophthalmology products in approved retinal indications (Faricimab for neovascular age-related macular degeneration \[nAMD\], diabetic macular edema \[DME\], and retinal vein occlusion; Port Delivery System with Ranibizumab for nAMD) in routine clinical practice. This study will not provide or make recommendations on use of any products including Roche products; treatment decisions will be determined by the treating physician and must be made independently to the decision to participate in this study. Participation in this study will not change or influence a patient's standard of care in any way.

Conditions

  • Neovascular Age-related Macular Degeneration
  • Diabetic Macular Edema
  • Retinal Vein Occlusion
  • Branch Retinal Vein Occlusion
  • Central Retinal Vein Occlusion
  • Hemi-retinal Vein Occlusion

Interventions

DRUG

Faricimab

Faricimab will be administered as per local clinical practice and local labeling.

COMBINATION_PRODUCT

Port Delivery System with Ranibizumab

The port delivery system with ranibizumab will be administered as per local clinical practice and local labeling.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-21
Primary Completion
2026-11-30
Completion
2027-11-30
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Australia
  • Bulgaria
  • Canada
  • Chile
  • Croatia
  • Czechia
  • Denmark
  • Egypt
  • France
  • Germany
  • Hong Kong
  • Israel
  • Italy
  • Japan
  • Poland
  • Puerto Rico
  • Saudi Arabia
  • Singapore
  • Slovenia
  • South Korea
  • Spain
  • Sweden
  • Switzerland
  • Taiwan
  • Thailand
  • United Arab Emirates
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05476926 on ClinicalTrials.gov